Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 1) Transcript

Dec 15, 2020 / 02:00PM GMT
Release Date Price: $135.7 (+2.27%)
Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning, and welcome to day 1 of our Virtual Alnylam R&D Day Event. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam.

With me today are John Maraganore, Chief Executive Officer, who'll provide some opening remarks and general context; Yvonne Greenstreet, President and Chief Operating Officer, who'll share an overview of our commercial progress; Akshay Vaishnaw, President of R&D, will discuss our approach to sustainable innovation before we take 2 deep dives, the first being on our Alnylam TTR franchise. In that session, we are pleased to have Dr. Philip Hawkins of the National Amyloidosis Center, Royal Free Hospital and University College London, join us alongside John Vest, Vice President of Clinical Research at Alnylam.

Additionally, we are excited to have Dr. Akshay Desai, Director, Cardiomyopathy and Heart Failure Program, Cardiovascular Division of Brigham and Women's Hospital, an Associate Professor of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot